Tango Therapeutics' Chief Legal Officer Resigns, Potential Impact on Company's Operations and Strategy

Tango Therapeutics has announced the resignation of its Chief Legal and Compliance Officer, effective September 12, 2025. The change may impact the company's operations and strategic direction. The most recent analyst rating on Tango Therapeutics stock is a Buy with a $11.00 price target. The overall stock score is Neutral due to significant financial challenges, including declining revenues and persistent losses. Technical analysis shows positive momentum, but the valuation remains unattractive.